Due to Xmas holidays, our last days of shipping will be as follow: International Dec 18, 2020. USA: Dec 21, 2020. The shipments will resume as usual on International: Jan 8, 2021 and USA: Jan 4, 2021.
PTC2 (PRKAR1A-RET), Active(R02-19CG)

PTC2 (PRKAR1A-RET), Active(R02-19CG)

  • $259.00


FOR BULK ORDER REQUESTS PLEASE CONTACT US

Description :Recombinant human RET/PTC2, the fusion protein [PRKAR1A (1-236)-RET (713-end)], was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag.

Species :Human

Tag :GST tag

Expression System:Sf9 insect cells using baculovirus

Sequence :PRKAR1A (1-236)-RET (713-end)

Genbank Number :NM_002734

Genbank Number 2 :NM_020630

Specific Activity :Sample Kinase Activity Plot. For specific information on a given lot, see related technical data sheet.

Purity :Sample Purity Data. For specific information on a given lot, see related technical data sheet.

Storage, Stability and Shipping :Store product at –70oC. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.

Applications :Kinase Assay, Western Blot

Molecular Weight :~105 kDa

Gene Aliases :PRKAR1A: CAR; CNC; CNC1; PKR1; PPNAD1; PRKAR1; TSE1 RET: CDHF12, RET51, PTC, RET-ELE1; RET/PTC2

References :
1. Gabriella S. et al: A t( 10; 17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Genes, Chromosomes and Cancer. 9:244-250 (1994).

2. M G Borrello, et al: The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol. May 1996; 16(5): 2151–2163.

Scientific Background :RET/PTC2 is fused of the tyrosine-kinase domain of proto-RET with the regulatory subunit R/A of c-AMP-dependent protein kinase A, by transforming a chromosomal translocation at t(10;17)(q11.2;q23) (1). The RET/PTC oncoproteins display constitutive TK activity and tyrosine phosphorylation. The RET/PTC2 Tyr-539 is an essential docking site for activating the SH2-containing transducer phospholipase PLCgamma (2). The RET/PTC2 activation may play crucial roles in papillary thyroid tumorigenesis and neoplastic oncogene.

Product Sheets (By Lot #) :

A1353-4.pdf

Research Areas :Cancer, Cancer, Neurobiology, Metabolic Disorder, Cell Cycle, Cellular Stress